{"id":"NCT02686138","sponsor":"Ardelyx","briefTitle":"A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C","officialTitle":"A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2017-08","completion":"2017-10","firstPosted":"2016-02-19","resultsPosted":"2020-04-13","lastUpdate":"2020-04-22"},"enrollment":593,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Constipation Predominant Irritable Bowel Syndrome"],"interventions":[{"type":"DRUG","name":"Tenapanor","otherNames":["RDX5791","AZD1722"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"50mg BID","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This phase 3, 26-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of one dose of Tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by the ROME III criteria and who have active disease as determined after a two-week screening period. Subjects who qualify and are randomized into the study will either receive 50mg BID of Tenapanor (1:1) for a 26 week treatment period.","primaryOutcome":{"measure":"Percentage of Subjects With Overall Response for 6 Out of 12 Weeks","timeFrame":"First 12 weeks","effectByArm":[{"arm":"50mg BID","deltaMin":107,"sd":null},{"arm":"Placebo","deltaMin":71,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":117,"countries":["United States"]},"refs":{"pmids":["33337659"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":293},"commonTop":["Diarrhea"]}}